

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Infectious disease				
Influenza virus	Galectin-9 (LGALS9)	<p>Mouse studies suggest blocking LGALS9 signaling could improve immune responses to influenza vaccines. In mice infected with influenza A virus, Lgals9 knockout led to a more robust immune response and better viral clearance than wild-type Lgals9 expression. In wild-type mice infected with influenza A virus, blocking Lgals9 signaling with a fusion protein increased immune responses compared with those seen using a control protein. Next steps could include using the fusion protein as a vaccine adjuvant in mouse models of influenza infection.</p> <p>SciBX 4(44); doi:10.1038/scibx.2011.1238 Published online Nov. 10, 2011</p>	Patent and licensing status unavailable	<p>Sharma, S. <i>et al. Proc. Natl. Acad. Sci. USA</i>; published online Nov. 3, 2011; doi:10.1073/pnas.1107087108 Contact: Barry T. Rouse, The University of Tennessee Knoxville, Knoxville, Tenn. e-mail: btr@utk.edu</p>